Recombinant Bovine Protein reprimo (RPRM)

What is Protein Reprimo (RPRM) and what are its key functions?

Protein Reprimo is the product of the single-exon RPRM gene located at chromosome 2q23, which encodes a highly glycosylated protein of 109 amino acids. RPRM functions primarily as a tumor suppressor through multiple mechanisms:

• Acts as a secretory protein that induces extrinsic apoptosis in recipient cells

• Mediates p53-dependent cell cycle arrest at the G2/M phase by inhibiting Cyclin B1·Cdc2 complex activation

• Inhibits cell proliferation, colony formation, migration, and invasiveness of cancer cells

• Participates in DNA damage response (DDR) pathways by negatively regulating ATM protein levels

RPRM has emerged as a crucial component in the newly identified p53–Reprimo–Hippo–YAP/TAZ–p73 axis that represents an extrinsic apoptosis pathway with a significant role in tumor suppression .

What expression systems are most effective for producing recombinant RPRM?

Recombinant RPRM can be successfully expressed and purified from several host systems, each with distinct advantages:

• E. coli and yeast systems: Offer the highest protein yields and shorter production turnaround times, making them suitable for initial structural studies and applications requiring large quantities

• Insect cells with baculovirus: Provide many essential post-translational modifications necessary for correct protein folding and moderate yields

• Mammalian cell expression systems: Ensure the most physiologically relevant post-translational modifications and are recommended when protein activity must be precisely maintained

The choice of expression system should be determined by the specific research application, with consideration for glycosylation patterns that may be crucial for RPRM functionality.

How is RPRM expression regulated at the cellular level?

RPRM expression is regulated through multiple mechanisms:

• Transcriptional regulation: RPRM is a direct target gene of p53 and is upregulated following DNA damage in p53-competent cells

• Epigenetic regulation: The RPRM promoter is frequently silenced by aberrant DNA methylation in various cancers including breast, gastric, pituitary, and pancreatic cancers

• Post-translational modification: RPRM is phosphorylated at serine 98 by CDK4/6, which appears to be involved in its nuclear translocation and interaction with ATM

• Stress-induced expression: X-irradiation and other genotoxic agents can induce RPRM expression in a p53-dependent manner

Understanding these regulatory mechanisms is essential for experimental design when investigating RPRM's role in normal physiology and pathological conditions.

What is the mechanism by which secreted RPRM induces extrinsic apoptosis?

The extrinsic apoptosis pathway induced by secreted RPRM involves a complex signaling cascade:

• Receptor binding: Secreted Reprimo protein binds to members of the protocadherin family, specifically identified as FAT1, FAT4, CELSR1, CELSR2, and CELSR3

• Hippo pathway activation: Following receptor binding, RPRM activates the Hippo signaling pathway

• YAP/TAZ regulation: The activated Hippo pathway leads to modulation of YAP/TAZ transcriptional co-activators

• p73-mediated transcription: The Hippo–YAP/TAZ–p73 axis is engaged, resulting in the transactivation of various proapoptotic genes

• Apoptosis execution: The upregulation of proapoptotic factors ultimately leads to programmed cell death in recipient cells

This pathway represents a novel extrinsic apoptosis mechanism distinct from the classical death receptor pathways and offers potential therapeutic applications in cancer treatment.

How does RPRM interact with the DNA damage response (DDR) pathway?

RPRM plays a multifaceted role in the DNA damage response pathway:

• ATM regulation: RPRM negatively regulates ATM protein levels by promoting nuclear-cytoplasmic translocation of ATM, resulting in its degradation

• Repair pathway inhibition: RPRM overexpression inhibits both homologous recombination (HR) and non-homologous end joining (NHEJ) DNA repair pathways

• Nuclear translocation: Upon DNA damage, RPRM translocates to the nucleus where it interacts with ATM

• Importin-mediated transport: The nuclear import of RPRM appears to involve Importin 11 (IPO11)

• CDK4/6-mediated phosphorylation: Phosphorylation of RPRM at serine 98 by CDK4/6 is involved in its function within the DDR pathway

This regulatory relationship between RPRM and ATM suggests that modulating RPRM levels could potentially be utilized to sensitize cancer cells to radiotherapy and other DNA-damaging treatments.

What experimental approaches can be used to study RPRM's tumor-suppressive effects in vivo?

Several experimental approaches have been employed to investigate RPRM's tumor-suppressive functions in vivo:

• Xenograft models: Implanting cells with controlled RPRM expression levels in immunodeficient mice to study tumor growth dynamics

• Genetic knockout models: RPRM-knockout mice have been used to study the impact of RPRM deficiency on radiation sensitivity and tissue response to radiation injury

• Whole-body irradiation (WBI): Used to evaluate the role of RPRM in radiation-induced systemic damage and survival

• Whole-abdominal irradiation (WAI): Applied to assess RPRM's function in protecting specific tissues like intestinal epithelium from radiation damage

• Recombinant protein administration: Direct administration of purified Reprimo protein into solid tumors to evaluate its ability to trigger apoptosis and suppress tumor growth

These approaches provide complementary insights into RPRM's functions in different physiological and pathological contexts.

What are the optimal conditions for expressing and purifying functional recombinant RPRM?

Optimizing recombinant RPRM production requires attention to several critical factors:

For functional studies, mammalian expression systems are preferred due to their ability to produce correctly folded and post-translationally modified RPRM .

How can researchers effectively measure RPRM-induced apoptosis in experimental settings?

Quantifying RPRM-induced apoptosis requires multi-parameter assessment:

• Morphological analysis:

  • Fluorescence microscopy with nuclear stains to visualize chromatin condensation

  • Transmission electron microscopy to observe ultrastructural changes

• Biochemical assays:

  • Annexin V/PI dual staining followed by flow cytometry to distinguish early and late apoptotic cells

  • TUNEL assay to detect DNA fragmentation

  • Caspase-3/7 activity assays to measure executioner caspase activation

• Molecular analyses:

  • Western blotting for cleaved PARP, cleaved caspases, and Bcl-2 family protein levels

  • RT-qPCR to quantify expression of apoptosis-related genes induced by the YAP/TAZ-p73 axis

  • ChIP assays to detect p73 binding to promoters of proapoptotic genes

• Live-cell imaging:

  • Time-lapse microscopy with fluorescent probes for real-time monitoring of apoptotic events

  • FRET-based sensors to monitor caspase activation kinetics

When designing experiments, researchers should include both direct treatment with recombinant RPRM protein and conditional expression systems to comprehensively evaluate apoptotic mechanisms.

What approaches can be used to validate RPRM receptor binding and signaling?

Validating RPRM-receptor interactions and downstream signaling requires multiple complementary techniques:

• Binding assays:

  • Surface Plasmon Resonance (SPR) to determine binding kinetics between purified RPRM and receptor ectodomains

  • Pull-down assays with tagged recombinant RPRM to identify interacting partners

  • Cross-linking followed by mass spectrometry to map interaction interfaces

• Cellular validation:

  • Proximity ligation assay (PLA) to visualize RPRM-receptor interactions in situ

  • CRISPR-Cas9 knockout of putative receptors (FAT1, FAT4, CELSR1-3) followed by functional rescue

  • Receptor blocking antibodies to inhibit RPRM-induced effects

• Signaling pathway analyses:

  • Phospho-specific antibodies to track Hippo pathway component activation

  • Luciferase reporter assays for TEAD-dependent transcription to measure YAP/TAZ activity

  • Co-immunoprecipitation to detect complex formation between YAP/TAZ and p73

• Functional validation:

  • Domain deletion mutants to identify critical regions of RPRM for receptor binding

  • Structure-function studies with recombinant RPRM variants

  • Competitive displacement assays with peptide fragments

These approaches collectively provide robust evidence for the proposed p53–Reprimo–Hippo–YAP/TAZ–p73 signaling axis in apoptosis induction.

What are the key challenges in developing RPRM-based cancer therapeutics?

The development of RPRM-based cancer therapeutics faces several significant challenges:

• Protein production and delivery:

  • Establishing cost-effective large-scale production of correctly folded RPRM

  • Developing effective delivery systems that can target RPRM to tumor sites

  • Ensuring stability of the protein in circulation and at the target site

• Targeting considerations:

  • Identifying cancer types most susceptible to RPRM-induced apoptosis

  • Determining whether RPRM receptors are expressed in target tumors

  • Evaluating potential off-target effects on normal tissues expressing RPRM receptors

• Resistance mechanisms:

  • Understanding potential adaptive responses that might limit efficacy

  • Identifying biomarkers that predict response to RPRM-based therapies

  • Developing combination strategies to overcome resistance

• Translational gaps:

  • Validating in vitro findings in physiologically relevant in vivo models

  • Establishing appropriate dosing regimens and administration schedules

  • Developing reliable companion diagnostics for patient selection

The potential of administering Reprimo protein or small molecules that mimic its functional properties into solid tumors represents a promising therapeutic strategy that warrants further investigation .

How can RPRM's dual role in tumor suppression and radiosensitization be reconciled for therapeutic applications?

The dual functionality of RPRM presents both opportunities and challenges for therapeutic development:

• Context-dependent targeting strategies:

  • For tumors with intact p53: Interventions to increase endogenous RPRM expression

  • For p53-mutant tumors: Direct delivery of recombinant RPRM or mimetics

  • For normal tissues during radiotherapy: Temporary RPRM inhibition to reduce radiosensitivity

• Temporal considerations:

  • Sequential therapy approaches where RPRM modulation is timed relative to other treatments

  • Pulsed administration strategies to maximize tumor-specific effects

• Molecular engineering approaches:

  • Development of tissue-specific RPRM variants with modified receptor binding profiles

  • Creation of conditionally active RPRM molecules that are activated in the tumor microenvironment

• Combination therapies:

  • Integration with DNA damage-inducing agents to enhance RPRM-mediated apoptosis

  • Co-targeting of ATM to augment RPRM's effects on DNA repair pathways

  • Combination with epigenetic modifiers to reverse RPRM promoter methylation in cancers

These approaches require careful experimental validation to balance therapeutic efficacy with potential toxicity to normal tissues.

What controls are essential when conducting RPRM functional studies?

Rigorous RPRM research requires comprehensive controls to ensure valid interpretation of results:

• Expression system controls:

  • Empty vector controls for all expression constructs

  • Inactive RPRM mutants (e.g., phosphorylation-site mutants)

  • Non-secreted RPRM variants (signal peptide deletions)

• Cell line considerations:

  • Matched p53 wild-type and null/mutant cell lines

  • RPRM knockout cell lines created via CRISPR-Cas9

  • Cell lines with varying expression levels of identified RPRM receptors

• Treatment controls:

  • Heat-inactivated RPRM protein

  • Conditioned media fractionation controls

  • Receptor-blocking antibody specificity controls

• Pathway validation:

  • Pharmacological inhibitors of Hippo pathway components

  • YAP/TAZ knockdown or knockout models

  • p73-deficient cellular models

These controls help distinguish direct RPRM effects from indirect or non-specific effects and validate the proposed signaling mechanisms.

How can researchers address potential contradictions in RPRM functional data?

When encountering contradictory findings regarding RPRM function, researchers should consider:

• Biological context variations:

  • Cell type-specific effects due to different receptor expression profiles

  • p53 status affecting RPRM induction and function

  • Differential pathway activation in various cellular contexts

• Methodological reconciliation:

  • Standardization of recombinant RPRM production and quality control

  • Consistent definition and measurement of endpoints

  • Cross-validation using multiple methodological approaches

• Dose and time-dependent responses:

  • Comprehensive dose-response studies with recombinant RPRM

  • Time-course analyses to distinguish immediate versus delayed effects

  • Consideration of biphasic responses across concentration ranges

• Integration with existing literature:

  • Systematic comparison with published datasets

  • Meta-analysis approaches to identify consistent patterns

  • Collaboration with other research groups to resolve discrepancies

A particular area requiring careful interpretation is the seemingly contradictory role of RPRM in both promoting apoptosis while also contributing to radioresistance when knocked out in certain contexts .